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Abstract
Introduction: Bisphosphonates are the most commonly used drugs for the prevention and treatment of osteoporosis. 
Although a recent FDA review of the results of clinical trials reported no clear link between bisphosphonates and 
serious or non-serious atrial fibrillation (AF), some epidemiologic studies have suggested an association between AF 
and bisphosphonates.
Methods: We conducted a meta-analysis of non-experimental studies to evaluate the risk of AF associated with 
bisphosphonates. Studies were identified by searching MEDLINE and EMBASE using a combination of the Medical 
Subject Headings and keywords. Our search was limited to English language articles. The pooled estimates of odds 
ratios (OR) as a measure of effect size were calculated using a random effects model.
Results: Seven eligible studies with 266,761 patients were identified: three cohort, three case-control, and one self-
controlled case series. Bisphosphonate exposure was not associated with an increased risk of AF [pooled multivariate 
OR 1.04, 95% confidence interval (CI) 0.92-1.16] after adjusting for known risk factors. Moderate heterogeneity was 
noted (I-squared score = 62.8%). Stratified analyses by study design, cohort versus case-control studies, yielded similar 
results. Egger's and Begg's tests did not suggest an evidence of publication bias (P = 0.90, 1.00 respectively). No clear 
asymmetry was observed in the funnel plot analysis. Few studies compared risk between bisphosphonates or by 
dosing.
Conclusions: Our study did not find an association between bisphosphonate exposure and AF. This finding is 
consistent with the FDA's statement.
Introduction
Osteoporosis is a major public health threat for an estimated
44 million Americans or 55% of the population 50 years of
age and older [1]. There were approximately two million
new fractures in the US in 2005 with a direct medical cost
of US$17 billion [2]. Bisphosphonates are the main therapy
for postmenopausal and glucocorticoid-induced osteoporo-
sis. Currently, four oral or intravenous forms of bisphos-
phonates (alendronate, risedronate, ibandronate, and
zoledronic acid) are approved for the treatment of osteopo-
rosis in the US. Known side effects of bisphosphonates
include gastrointestinal mucosal irritation, such as esopha-
geal ulcer, bone pain, muscle cramps or pain, hyperphos-
phatemia, hypocalcemia, and rarely osteonecrosis of the
jaw [3,4].
An increased risk of atrial fibrillation (AF) has been
noted with use of bisphosphonates, especially with intrave-
nous zoledronic acid [5-7]. AF is the most common
arrhythmia among older adults. Common risk factors
include older age, male gender, dilated cardiomyopathy,
diabetes, hypertension, coronary artery disease, obstructive
sleep apnea, cardiac surgery, high-dose corticosteroid ther-
apy, alcohol excess, and alcohol withdrawal [8-10]. AF
contributes to approximately 35% of strokes in an octoge-
narian population, increases the overall risk of stroke by
five-fold, and is associated with particularly severe strokes
[11]. With the aging population, AF and its consequences
will become an increasingly common medical and eco-
nomic problem.
In October 2007, the US Food and Drug Administration
(FDA) first announced that the agency was assessing the
potential risk of AF associated with bisphosphonate use
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[12]. After reviewing data from spontaneous post-market-
ing reports and clinical trials of bisphosphonates, the FDA
stated that healthcare providers and patients should not
change either their prescribing practices or their use of bis-
phosphonates [12]. A year later, the FDA released updated
information based on further information from four pla-
cebo-controlled clinical trials and concluded that there was
no clear association between bisphosphonate exposure and
the rate of serious or non-serious AF events [13]. At that
time, the FDA stated that that they would explore the feasi-
bility of conducting additional epidemiologic studies to fur-
ther examine the issue. Subsequently, a number of large
population-based studies examining the risk of AF with bis-
phosphonates have been published [7,14-19]. The results
from two meta-analytic studies [20,21] are also available
but information one could draw from these studies are
somewhat limited owing to a small study size and signifi-
cant heterogeneity among the included studies. Population-
based epidemiologic studies offer several advantageous
over clinical trial data, particularly to study unexpected and
rare adverse reactions such as AF in bisphosphonate users
(incidence rate of AF is less than 2 per 100 person-year
[14,17]). Clinical trials are often underpowered to detect
rare adverse events and lack of generalizability owing to
specific inclusion and exclusion criteria [22]. Given such
potential limitations of clinical trials and meta-analyses of
clinical trials, we therefore conducted a systematic review
and meta-analysis of non-experimental studies to determine
the association between the use of bisphosphonates and the
risk of AF or flutter.
Materials and methods
Data sources
We searched two major electronic databases -- MEDLINE
(1981 to September 2009), EMBASE (1981 to September
2009) -- for studies of the association between AF and the
use of bisphosphonates in patients with osteoporosis. We
also searched abstracts from scientific meetings (American
College of Rheumatology and International Conference on
Pharmacoepidemiology and Therapeutic Risk Manage-
ment) and bibliographies of identified reports and review
articles for additional references. We imposed no geo-
graphic restrictions. Our search strategy is described in Fig-
ure 1. Only studies published in English were included.
Study eligibility and selection
To be eligible for inclusion, we only considered population-
based non-experimental studies of adult patients, studies
reporting the risk of AF or flutter associated with bisphos-
phonate use, and studies examining the effects of bisphos-
phonates for the prevention or treatment of osteoporosis or
fractures. Studies of patients with malignancy such as
breast or prostate cancer were excluded. Two authors (SYK
and MJK) independently screened each of the potential
titles, abstracts, and/or full-texts to determine if they were
eligible for inclusion. Areas of disagreement or uncertainty
were resolved by consensus.
Data abstraction and quality assessment
All data were independently abstracted in duplicate by two
authors (SYK and MJK) using a data abstraction form. Data
on the study characteristics, such as author name, year of
publication, country, sample size, mean age of patients,
type of bisphosphonate used, and number of outcome,
unadjusted and multivariate, or adjusted, and risk of AF,
were collected. The Newcastle-Ottawa Scale was used to
assess the quality of studies [23] (Tables 1 and 2). A quality
score was calculated on the basis of three major compo-
nents: selection of the study groups (0 to 4 points), quality
of the adjustment for confounding (0 to 2 points) and ascer-
tainment of the outcome of interest in the cohorts (0 to 3
points). A higher score represents better methodological
quality. Adjustment for known AF risk factors, duration of
follow up of at least one year for cohort studies, and ade-
quate outcome ascertainment were criteria of higher quality.
Statistical analysis
We chose to use odds ratio (OR) as a measure of effect size
because it is one of the most commonly used effect mea-
sures for observational studies [24]. We assumed that either
relative risk or hazard ratio was equivalent to OR as the
probability of the outcome, AF, was expected to be low
[25]. Pooled estimates of multivariate ORs were calculated
using the DerSimonian and Laird random effects model
[26,27] for AF. This statistical technique weighs individual
studies by sample size and variance (both within- and
between-study variance) and yields a pooled point estimate
of OR and a 95% confidence interval (CI). The DerSimo-
nian and Laird technique was considered an appropriate
pooling technique because of the relative heterogeneity of
the source population in each study. Subgroup analysis by
study design was performed. We also evaluated the pres-
ence of heterogeneity across trials by using the I2 statistic,
Figure 1 Search strategy.
MeSH  Headings:       Keywords:   
 
1.  exp Bone Density Conservation 
Agents 
2.  exp Osteoporosis OR exp 
Osteoporosis, Postmenopausal 
3.  exp Alendronate   
4.  exp Etidronic Acid  
5.  exp Diphosphonates 
6.  exp Atrial Fibrillation  
7.  exp Atrial Flutter  
8.  exp Arrhythmias, Cardiac 
 
 
17.  1 OR 2 OR 3 OR 4 OR 5  
18.  9 OR 10 OR 11 OR 12 OR 13  
19.  17 OR 18  
20.  6 OR 7 OR 8  
21.  14 OR 15 OR 16  
22.  20 OR 21  
23.  19 AND 22   
 
9. Alendronate 
10. Fosamax  
11. Risedronate OR Actonel 
12. Ibandronate OR Boniva  
13. Zoledronate OR Zoledronic acid 
OR Reclast  
14. Atrial fibrillation   
15. Atrial flutter 
16. Arrhythmia   
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Table 1: Summary of included cohort studies and characteristics
Study, year, 
country
Subjects Mean age
(years)
Mean follow-
up (years)
Type of bisphosphonate AF definition Total AF 
events (n)
Variables 
matched and/or 
controlled
Quality 
assessment
score§
Bunch and 
colleagues [15], 
2009, USA
9,623 (98 BIS 
users and 9,525 
non-users) in 
angiographic 
research 
database
60 4.1 Alendronate
Etidronate
Ibandronate
Risedronate
Zoledronic acid
Hospital 
discharge ICD-9 
codes and EKG 
data
974 Age, HTN, 
hyperlipidemia, 
DM, HF, CAD, etc
4/2/3
37,485 (7,489 
BIS users and 
29,996 non-
users) in a 
commercial 
health care 
system 
database
51 4.6 1012
Abrahamsen and 
colleagues [14], 
2009, Denmark
43,033 patients 
(14,302 BIS 
users and 
28,731 non-
users) with 
fractures in the 
National 
Hospital 
Discharge 
register
74 2.7 Alendronate
Clodronate
Etidronate
Ibandronate
Risedronate
Prescription for 
a cardiac 
glycoside +/- 
ICD-10 codes
797 * Age, gender, 
fracture sites, 
medications use 
for DM, HTN, 
hypercholesterol
emia, and 
thrombosis, and 
Charlson index
4/2/3
Huang and 
colleagues [17], 
2009, Taiwan
27,257 women 
(21,037 BIS 
users and 6,220 
raloxifene 
users) with 
osteoporosis in 
the National 
Health 
Insurance 
database
74 0.6 Alendronate Inpatient or 
outpatient ICD-9 
codes
821 DM, CAD, COPD, 
history of AF, 
HTN, and total 
defined daily 
dose of drugs
3/2/2
* only in BIS users, § Methodologic quality assessment score based on Newcastle-Ottawa Scale [23]; selection (0 to 4), comparability (0 to 2), and outcome score (0 to 3) points with a higher score representing a 
better quality.
AF, atrial fibrillation; BIS, bisphosphonates; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; EKG, electrocardiogram; HF, heart failure; HTN, hypertension; ICD, 
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which quantifies the percentage of variability that can be
attributed to between-study differences [28]. Sensitivity
analysis was performed to examine the effect of studies
lacking information on methodologic quality on the pooled
estimates. To assess the potential for publication bias, we
performed the Begg's and the Egger's tests and constructed
funnel plots to visualize possible asymmetry [29]. Due to
the limited number of studies, no further subgroup analysis
or meta-regression was considered. All statistical analyses
were performed in Stata 10 (Stata Corp, College Station,
TX, USA). We followed the Meta-analyses of Observa-
tional Studies in Epidemiology guidelines [30] in the report
of this meta-analysis.
Table 2: Summary of included case-control studies and characteristics
Study, 
Year, 
Country
Subjects Mean 
age
(year)
Mean 
duration 
(year)
Type of 
bisphosphonate
AF 
definition
Total AF 
events (n)
Variables 
matched 
and/or 
controlled
Quality 
assessment
score§
Heckbert 
and 
colleagues 
[7], 2008, 
USA
1,685 
women in a 
commercial 
health care 
system 
database
73 20 Alendronate ICD-9 
codes 
verified by 
medical 
records +/- 
EKG
719 Age, HTN, 
calendar 
year, 
osteoporo
sis, and 
any 
cardiovasc
ular 
disease
4/2/3
Sorensen 
and 
colleagues 
[19], 2008, 
Denmark
81,640 
women in 
the 
National 
Registry of 
Patients
>75 Not 
reported
Alendronate
Etidronate
ICD-8 and 
10 codes
13586 Age, 
county, 
cardiovasc
ular 
disease, 
renal 
failure, 
DM, HRT, 
fracture, 
cancer, 
alcoholism
, 
pulmonary 
disease, 
anti-
thyroid 
drugs, 
osteoporo
sis, steroid 
use, etc
3/2/3
Grosso and 
colleagues
* [16], 
2009, UK
2,195 
women 
with AF in 
the UK 
General 
Practice 
Research 
Database
82 13 Alendronate
Risedronate
Diagnosis 
codes and 
Read 
codes
2195 Age+ 3/2/3
Levesque 
and 
colleagues 
[18], 2009, 
Canada
63,843 
adults (BIS 
users and 
raloxifene 
users) in the 
Quebec 
health 
database
75 4 Alendronate
Etidronatea
Risedronatea
Not 
reported
2149 Age, 
cohort 
entry year, 
follow-up, 
CAD, HTN, 
and use of 
HRT
N/A
AF, atrial fibrillation; BIS, bisphosphonates; CAD, coronary artery disease; DM, diabetes mellitus; EKG, electrocardiogram; HRT, hormone replacement 
therapy; HTN, hypertension; ICD, International Classification of Diseases.
* self-controlled case-series. + no other adjustment not needed in self-controlled study, N/A, not applicable (only the abstract was available at the time of 
this study), a risks specific to etidronate or risedronate not used in meta-analysis, § Methodologic quality assessment score based on Newcastle-Ottawa Scale 
[23]; selection (0 to 4), comparability (0 to 2), and outcome score (0 to 3) points with a higher score representing a better quality.Kim et al. Arthritis Research & Therapy 2010, 12:R30
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Results
Study characteristics and quality
The electronic search retrieved 160 potentially relevant ref-
erences (Figure 2). A manual search of bibliographies of
relevant review papers and the published abstracts of the
annual meetings of the American College of Rheumatology
and the International Conference on Pharmacoepidemiol-
ogy (2008 to 2009) identified five additional references. On
initial screening, 156 of 165 were excluded based on titles
and abstracts. Nine full-text articles were subsequently
retrieved for detailed evaluation. Of those, seven studies -
three cohort, three case-control, and one self-controlled
case series [7,14-19] - representing data from 266,761
patients were finally included in the meta-analysis and two
systematic reviews [20,21] were excluded. The characteris-
tics of the included studies and of their participants are
summarized in Tables 1 and 2. The self-controlled case
series study by Grosso and colleagues [16] was considered
as a case-control study for analysis.
One study was completed in Taiwan [17], and all others
used population-based data from either North America
[7,15,18] or Europe [14,16,19]. The number of subjects in
each study ranged from 1,685 to 81,640. The majority of
study subjects were aged over 70 years. Two studies com-
pared bisphosphonate users with raloxifene users [17,18]
and the rest compared bisphosphonate users with non-users
[7,14-16,19]. One study [15] included zoledronic acid and
the others only considered oral bisphosphonates. In the
study by Levesque and colleagues [18], the risk of AF spe-
cific to alendronate, risedronate, and etidronate was
reported; however, only the risk of AF among alendronate
users was included in our meta-analysis because the major-
ity of the included studies focused on either alendronate or
a combination of different bisphosphonates as a drug class.
Results from two different patient cohorts were available in
the study by Bunch and colleagues [15].
Most studies were of moderate to high quality although
only three studies defined the outcome of AF based on a
combination of diagnosis codes and clinical records
[7,14,15]. Quality of the study by Levesque and colleagues
[18] was not assessed because it was only available as an
abstract.
Bisphosphonates and atrial fibrillation
The overall pooled estimate of multivariate OR for AF
based on eight patient cohorts from seven studies adjusting
for known AF risk factors was 1.04 (95% CI = 0.92 to 1.16;
Figure 3). Moderate heterogeneity was noted (I2 = 62.8%, P
= 0.009). Our subgroup analysis stratified by study design
yielded similar results. The pooled estimate of multivariate
OR based on three cohort studies [14,15,17] was 1.01 (95%
CI = 0.80 to 1.23) with moderate-to-severe heterogeneity
(I2 = 75.7%, P = 0.01). The pooled estimate of multivariate
OR based on four case-control studies [7,16,18,19] was
1.05 (95% CI = 0.91 to 1.19) with moderate heterogeneity
(I2 = 45.4%, P = 0.14).
Sensitivity analysis was carried out by excluding the
study by Levesque and colleagues [18], of which quality
was not known. The pooled estimate of multivariate OR
remained almost the same (1.03; 95% CI = 0.90 to 1.15).
Publication bias assessment
The funnel plot was visually examined and did not reveal
any obvious asymmetry (Figure 4). There was no statistical
evidence of publication bias among the included studies by
using Egger's (P = 0.90) and Begg's (P = 1.00) tests.
Discussion
Although a few plausible mechanisms exist for the associa-
tion between the use of bisphosphonates and AF -- electro-
lyte imbalance such as hypocalcemia or bisphosphonate-
induced inflammation affecting atrial remodeling and fibro-
sis [31-34] - our meta-analysis of non-experimental studies
found no significant association between bisphosphonate
exposure and AF.
It is possible that our result was negative because mild or
asymptomatic AF cases were missed in large non-experi-
mental studies, because the majority of the included studies
defined outcomes mainly with diagnosis codes. Also, as
there is only a small fraction of patients exposed to intrave-
nous forms of bisphosphonates such as ibandronate or zole-
dronic acid in our meta-analysis, it still remains uncertain
whether the risk of AF increases with intravenous bisphos-
phonates. Our study is consistent with the FDA's safety
review and supported by two previously published meta-
analyses [20,21]. In the previous meta-analysis of four ran-
domized clinical trials based on total 519 (230 serious, 289
non-serious) AF events among 26,352 patients [20], a sig-
nificant association was observed between the risk of seri-
ous AF events and use of bisphosphonates (OR = 1.47; 95%
CI = 1.01 to 2.14), but no significant association was noted
for any AF events (OR = 1.14, 95% CI = 0.96 to 1.36). The
Figure 2 Selection of studies included in the analysis.
165 potentially relevant references 
Identified 
9 full text articles retrieved for  
detailed evaluation  
7 references in the meta-analysis:  
3 cohort, 3 case-control and 1 self-
controlled case series  
156 references 
excluded by title and 
abstract reviews  
2 systematic reviews 
excluded  Kim et al. Arthritis Research & Therapy 2010, 12:R30
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elevated risk of serious AF might have been overestimated
as two of the four clinical trials [5,6,35,36] were performed
to study the effect of monthly zoledronic acid infusion on
osteoporosis [5,36]. Another meta-analysis by Mak and col-
leagues [21] showed no evidence of an increased risk of AF
related to bisphosphonate use in their meta-analysis of four
randomized clinical trials [5,6,36,37] and three non-experi-
mental studies (one cohort and two case-control studies)
[7,14,19]. The pooled estimate of crude ORs based on three
non-experimental studies [7,14,19] was 1.25 (95% CI =
0.98 to 1.73). Our study included four additional studies
[15-18] that were not analyzed in any of previous meta-
analyses and yielded similar results.
Several other limitations of our study should be noted.
Due to a relatively small number of studies included in our
analysis, we were unable to examine the risk of AF relative
to the type or dose of bisphosphonates. Non-experimental
studies are subject to measured and unmeasured confound-
ing and other biases. Thus, our meta-analysis may suffer
these limitations as well. Not every study included in our
meta-analysis was adjusted for all the potential risk factors
of AF, as observed in Tables 1 and 2. As raw data of indi-
vidual studies were not available to us, we pooled the multi-
variate, or adjusted, ORs from the final model of each
study. In addition, significant heterogeneity between studies
Figure 3 Random effects analysis of the studies for the association between AF and bisphosphonate exposure, adjusted for known risk fac-
tors. Points (dot) and overall (diamond) estimates are given as odds ratios (OR) with 95% confidence interval (CI) (horizontal bar), AF, atrial fibrillation.
 
Figure 4 Begg's funnel plot for publication bias assessment. The 
size of circle represents the weight of each study in our analysis. OR, 
odds ratio; se, standard error.
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was noted, as often expected in meta-analyses of observa-
tional studies [38,39]. In order to account for both within-
and between-study variance, we used a random effects
model for our analysis. Potential sources of heterogeneity
between the studies include variations in the study size,
patient characteristics (age, gender, geographic location,
underlying comorbidities and use of other drugs), type of
bisphosphonates, exposure and outcome ascertainment
methods, and the study quality. Due to the limited number
of the included studies in our analysis, we could not further
identify causes of heterogeneity using the meta-regression
technique. Although all meta-analyses are inherently vul-
nerable to publication bias, we attempted to minimize this
bias by searching two major electronic databases with no
geographic restriction. Three different statistical tests
examined the issue of publication bias and revealed no sta-
tistical evidence for significant publication bias.
Our study also has several important strengths. This
meta-analysis is up to date and comprehensive including
seven large epidemiologic studies conducted in various
countries [7,14-19]. We assessed the quality of individual
studies using the Newcastle-Ottawa Scale [23]. The major-
ity of the included studies had adequate sample sizes, fol-
low-up lengths (applicable for cohort studies only), and
adjustments for known AF risk factors. Our pooled esti-
mates are based on multivariate ORs of individual studies
adjusting for a number of known AF risk factors. We fur-
thermore provided a subgroup analysis of the studies by
study design and yielded a similar result.
Conclusions
Our meta-analysis of published non-experimental studies
suggests that there is no increased risk of AF associated
with the use of bisphosphonates for osteoporosis. Physi-
cians should be vigilant for all potential drug-associated
toxicities, although the use of oral bisphosphonates proba-
bly does not increase a risk of AF, independent of known
risk factors for AF. Future research studying a risk associ-
ated with intravenous bisphosphonates or a dose-response
relation might provide further information.
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